Design of a peptide-based vaccine against human respiratory syncytial virus using a reverse vaccinology approach: evaluation of immunogenicity, antigenicity, allergenicity, and toxicity.

ABSTRACT:

Background

Attempts to develop an hRSV vaccine have faced safety and efficacy challenges, with only three FDA-approved vaccines (Moderna's Mresvia, Pfizer's Abrysvo, and GSK's Arexvy) available. These vaccines are limited to individuals over 60 years, require boosters, and only reduce disease severity without clearing the infection. Therefore, we employed a reverse vaccinology approach in this study to identify the most promising antigenic epitopes capable of eliciting a robust and protective immune response.

Methodology

This study employed computational techniques to design a novel multi-epitope vaccine targeting hRSV. Using bioinformatics tools, candidate epitopes were identified from conserved viral proteins (F and G glycoproteins), assessing their immunogenicity, antigen

SUBMITTER: Alnajran H 

PROVIDER: S-EPMC11986473 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature